Australia markets closed

Corcept Therapeutics Incorporated (CORT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
21.00+0.89 (+4.43%)
At close: 04:00PM EDT
20.90 -0.10 (-0.48%)
After hours: 07:46PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 2.17B
Enterprise value 1.83B
Trailing P/E 22.44
Forward P/E 22.32
PEG ratio (5-yr expected) N/A
Price/sales (ttm)6.57
Price/book (mrq)5.32
Enterprise value/revenue 4.80
Enterprise value/EBITDA 13.56

Trading information

Stock price history

Beta (5Y monthly) 0.54
52-week change 3-2.51%
S&P500 52-week change 3-1.04%
52-week high 325.68
52-week low 315.83
50-day moving average 322.15
200-day moving average 320.95

Share statistics

Avg vol (3-month) 3966.41k
Avg vol (10-day) 3721.94k
Shares outstanding 5106.25M
Implied shares outstanding 6N/A
Float 886.9M
% held by insiders 110.90%
% held by institutions 177.97%
Shares short (12 May 2022) 420.3M
Short ratio (12 May 2022) 419
Short % of float (12 May 2022) 429.65%
Short % of shares outstanding (12 May 2022) 419.11%
Shares short (prior month 13 Apr 2022) 416.56M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin 29.41%
Operating margin (ttm)34.61%

Management effectiveness

Return on assets (ttm)16.12%
Return on equity (ttm)24.35%

Income statement

Revenue (ttm)380.23M
Revenue per share (ttm)3.37
Quarterly revenue growth (yoy)17.90%
Gross profit (ttm)360.7M
EBITDA 132.71M
Net income avi to common (ttm)111.84M
Diluted EPS (ttm)0.91
Quarterly earnings growth (yoy)-2.80%

Balance sheet

Total cash (mrq)345.53M
Total cash per share (mrq)3.25
Total debt (mrq)2.82M
Total debt/equity (mrq)0.69
Current ratio (mrq)6.78
Book value per share (mrq)3.84

Cash flow statement

Operating cash flow (ttm)177.72M
Levered free cash flow (ttm)139.04M